vs
Side-by-side financial comparison of Merck & Co. (MRK) and Warner Bros. Discovery (WBD). Click either name above to swap in a different company.
Merck & Co. is the larger business by last-quarter revenue ($16.4B vs $9.5B, roughly 1.7× Warner Bros. Discovery). Merck & Co. runs the higher net margin — 18.1% vs -2.7%, a 20.7% gap on every dollar of revenue. On growth, Merck & Co. posted the faster year-over-year revenue change (5.0% vs -5.7%). Merck & Co. produced more free cash flow last quarter ($1.8B vs $1.4B). Over the past eight quarters, Merck & Co.'s revenue compounded faster (2.0% CAGR vs -2.5%).
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
Warner Bros. Discovery, Inc. (WBD) is an American multinational mass media and entertainment conglomerate headquartered in New York City. It was formed from WarnerMedia's spin-off by AT&T and merger with Discovery, Inc. on April 8, 2022.
MRK vs WBD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.4B | $9.5B |
| Net Profit | $3.0B | $-252.0M |
| Gross Margin | 66.2% | — |
| Operating Margin | 20.9% | 3.7% |
| Net Margin | 18.1% | -2.7% |
| Revenue YoY | 5.0% | -5.7% |
| Net Profit YoY | -20.8% | 49.0% |
| EPS (diluted) | $1.19 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.4B | $9.5B | ||
| Q3 25 | $17.3B | $9.0B | ||
| Q2 25 | $15.8B | $9.8B | ||
| Q1 25 | $15.5B | $9.0B | ||
| Q4 24 | $15.6B | $10.0B | ||
| Q3 24 | $16.7B | $9.6B | ||
| Q2 24 | $16.1B | $9.7B | ||
| Q1 24 | $15.8B | $10.0B |
| Q4 25 | $3.0B | $-252.0M | ||
| Q3 25 | $5.8B | $-148.0M | ||
| Q2 25 | $4.4B | $1.6B | ||
| Q1 25 | $5.1B | $-453.0M | ||
| Q4 24 | $3.7B | $-494.0M | ||
| Q3 24 | $3.2B | $135.0M | ||
| Q2 24 | $5.5B | $-10.0B | ||
| Q1 24 | $4.8B | $-966.0M |
| Q4 25 | 66.2% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 77.5% | — | ||
| Q1 25 | 78.0% | — | ||
| Q4 24 | 75.5% | — | ||
| Q3 24 | 75.5% | — | ||
| Q2 24 | 76.8% | — | ||
| Q1 24 | 77.6% | — |
| Q4 25 | 20.9% | 3.7% | ||
| Q3 25 | 39.0% | 6.8% | ||
| Q2 25 | 31.6% | -1.9% | ||
| Q1 25 | 38.0% | -0.4% | ||
| Q4 24 | 26.7% | 1.6% | ||
| Q3 24 | 24.6% | 2.9% | ||
| Q2 24 | 37.3% | -105.1% | ||
| Q1 24 | 35.9% | -2.7% |
| Q4 25 | 18.1% | -2.7% | ||
| Q3 25 | 33.5% | -1.6% | ||
| Q2 25 | 28.0% | 16.1% | ||
| Q1 25 | 32.7% | -5.0% | ||
| Q4 24 | 24.0% | -4.9% | ||
| Q3 24 | 19.0% | 1.4% | ||
| Q2 24 | 33.9% | -102.8% | ||
| Q1 24 | 30.2% | -9.7% |
| Q4 25 | $1.19 | $-0.10 | ||
| Q3 25 | $2.32 | $-0.06 | ||
| Q2 25 | $1.76 | $0.63 | ||
| Q1 25 | $2.01 | $-0.18 | ||
| Q4 24 | $1.49 | $-0.20 | ||
| Q3 24 | $1.24 | $0.05 | ||
| Q2 24 | $2.14 | $-4.07 | ||
| Q1 24 | $1.87 | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.6B | $4.6B |
| Total DebtLower is stronger | — | $32.4B |
| Stockholders' EquityBook value | $52.6B | $35.9B |
| Total Assets | $136.9B | $100.1B |
| Debt / EquityLower = less leverage | — | 0.90× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.6B | $4.6B | ||
| Q3 25 | $18.2B | $4.3B | ||
| Q2 25 | $8.6B | $4.9B | ||
| Q1 25 | $9.2B | $3.9B | ||
| Q4 24 | $13.7B | $5.3B | ||
| Q3 24 | $14.6B | $3.3B | ||
| Q2 24 | $11.4B | $3.6B | ||
| Q1 24 | $5.6B | $3.0B |
| Q4 25 | — | $32.4B | ||
| Q3 25 | — | $33.4B | ||
| Q2 25 | — | $34.4B | ||
| Q1 25 | — | $34.6B | ||
| Q4 24 | — | $36.8B | ||
| Q3 24 | — | $37.2B | ||
| Q2 24 | — | $37.3B | ||
| Q1 24 | — | $39.1B |
| Q4 25 | $52.6B | $35.9B | ||
| Q3 25 | $51.9B | $36.0B | ||
| Q2 25 | $49.0B | $36.0B | ||
| Q1 25 | $48.3B | $33.8B | ||
| Q4 24 | $46.3B | $34.0B | ||
| Q3 24 | $44.5B | $35.1B | ||
| Q2 24 | $43.6B | $34.3B | ||
| Q1 24 | $40.4B | $44.2B |
| Q4 25 | $136.9B | $100.1B | ||
| Q3 25 | $129.5B | $100.5B | ||
| Q2 25 | $117.5B | $101.7B | ||
| Q1 25 | $115.1B | $101.7B | ||
| Q4 24 | $117.1B | $104.6B | ||
| Q3 24 | $117.5B | $106.3B | ||
| Q2 24 | $112.6B | $108.0B | ||
| Q1 24 | $105.8B | $119.8B |
| Q4 25 | — | 0.90× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | — | 1.08× | ||
| Q3 24 | — | 1.06× | ||
| Q2 24 | — | 1.09× | ||
| Q1 24 | — | 0.89× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.9B | $1.8B |
| Free Cash FlowOCF − Capex | $1.8B | $1.4B |
| FCF MarginFCF / Revenue | 11.1% | 14.6% |
| Capex IntensityCapex / Revenue | 6.3% | 4.5% |
| Cash ConversionOCF / Net Profit | 0.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $12.4B | $3.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9B | $1.8B | ||
| Q3 25 | $7.8B | $979.0M | ||
| Q2 25 | $3.3B | $983.0M | ||
| Q1 25 | $2.5B | $553.0M | ||
| Q4 24 | $3.5B | $2.7B | ||
| Q3 24 | $9.3B | $847.0M | ||
| Q2 24 | $5.6B | $1.2B | ||
| Q1 24 | $3.1B | $585.0M |
| Q4 25 | $1.8B | $1.4B | ||
| Q3 25 | $6.8B | $701.0M | ||
| Q2 25 | $2.5B | $702.0M | ||
| Q1 25 | $1.2B | $302.0M | ||
| Q4 24 | $2.5B | $2.4B | ||
| Q3 24 | $8.5B | $632.0M | ||
| Q2 24 | $4.8B | $976.0M | ||
| Q1 24 | $2.2B | $390.0M |
| Q4 25 | 11.1% | 14.6% | ||
| Q3 25 | 39.6% | 7.8% | ||
| Q2 25 | 16.0% | 7.2% | ||
| Q1 25 | 7.5% | 3.4% | ||
| Q4 24 | 16.1% | 24.2% | ||
| Q3 24 | 51.1% | 6.6% | ||
| Q2 24 | 30.1% | 10.0% | ||
| Q1 24 | 14.1% | 3.9% |
| Q4 25 | 6.3% | 4.5% | ||
| Q3 25 | 5.7% | 3.1% | ||
| Q2 25 | 4.8% | 2.9% | ||
| Q1 25 | 8.6% | 2.8% | ||
| Q4 24 | 6.0% | 2.9% | ||
| Q3 24 | 4.7% | 2.2% | ||
| Q2 24 | 4.9% | 2.6% | ||
| Q1 24 | 5.5% | 2.0% |
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 0.74× | 0.62× | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.92× | — | ||
| Q3 24 | 2.94× | 6.27× | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | 0.65× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRK
| Pharmaceuticalsegment | $8.7B | 53% |
| Keytruda | $4.9B | 30% |
| Other | $2.7B | 16% |
| Janumet | $57.0M | 0% |
| Isentress Isentress HD | $38.0M | 0% |
| Pifeltro | $25.0M | 0% |
| Belsomra | $23.0M | 0% |
| Dificid | $17.0M | 0% |
| Delstrigo | $14.0M | 0% |
| Lagevrio | $12.0M | 0% |
| Pneumovax23 | $4.0M | 0% |
WBD
| Distribution Revenue | $4.8B | 51% |
| Global Linear Networks | $4.2B | 44% |
| Service Other | $307.0M | 3% |
| Related Party | $204.0M | 2% |
| Other | $7.0M | 0% |
